載入...
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells
Early phase clinical trials evaluating CD8+ T cell-eliciting, HER2-derived peptide vaccines administered to HER2-positive breast cancer patients in the adjuvant setting suggest synergy between the vaccines and trastuzumab, the monoclonal antibody targeting the HER2 protein. Among 60 patients enrolle...
Na minha lista:
| 發表在: | Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5626640/ https://ncbi.nlm.nih.gov/pubmed/28819024 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-2774 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|